Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab

O. Fiala, T. Buchler, B. Mohelnikova-Duchonova, B. Melichar, VM. Matejka, L. Holubec, J. Kulhankova, Z. Bortlicek, M. Bartouskova, V. Liska, O. Topolcan, M. Sedivcova, J. Finek,

. 2016 ; 37 (5) : 6823-30. [pub] 20151210

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17014196

The v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in 35-45 % of colorectal cancer (CRC) cases. Although the association between the RAS signaling and angiogenesis is well known, the negative predictive value of KRAS mutation has not been established in patients treated with bevacizumab. The aim of this study was to evaluate the association between specific KRAS mutation types and outcome of patients with metastatic CRC treated with bevacizumab. The study included 404 patients with metastatic CRC (mCRC) treated with bevacizumab. Clinical data obtained from the clinical registry CORECT were retrospectively analyzed. The shortest survival was observed in patients with tumors harboring G12V or G12A KRAS mutation (G12V/A). The median progression-free survival (PFS) and overall survival (OS) for patients with tumors harboring G12V/A KRAS mutation was 6.6 and 16.8 compared to 11.6 and 26.3 months for patients with tumors harboring other KRAS mutation type (p < 0.001 and p < 0.001), while the survival of patients harboring other KRAS mutation types was comparable to those with tumors harboring wild-type KRAS gene. In the Cox multivariable analysis, KRAS G12V/A mutation type remains a significant factor predicting both PFS (HR = 2.18, p < 0.001) and OS (HR = 2.58, p < 0.001). In conclusion, the results of the present study indicate that there is a significant difference in biological behavior between tumors harboring G12V/A and other KRAS mutations. Moreover, comparison of the survival of patients with tumors harboring G12V/A KRAS mutations with those harboring wild-type KRAS gene revealed that G12V/A KRAS mutations are prognostic biomarker for inferior PFS and OS in patients with mCRC treated with bevacizumab in univariate as well as multivariable analyses.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17014196
003      
CZ-PrNML
005      
20171213084306.0
007      
ta
008      
170413s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s13277-015-4523-7 $2 doi
035    __
$a (PubMed)26662311
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University in Prague, alej Svobody 80, CZ-304 60, Pilsen, Czech Republic. fiala.o@centrum.cz. Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Plzeň, Czech Republic. fiala.o@centrum.cz.
245    10
$a G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab / $c O. Fiala, T. Buchler, B. Mohelnikova-Duchonova, B. Melichar, VM. Matejka, L. Holubec, J. Kulhankova, Z. Bortlicek, M. Bartouskova, V. Liska, O. Topolcan, M. Sedivcova, J. Finek,
520    9_
$a The v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in 35-45 % of colorectal cancer (CRC) cases. Although the association between the RAS signaling and angiogenesis is well known, the negative predictive value of KRAS mutation has not been established in patients treated with bevacizumab. The aim of this study was to evaluate the association between specific KRAS mutation types and outcome of patients with metastatic CRC treated with bevacizumab. The study included 404 patients with metastatic CRC (mCRC) treated with bevacizumab. Clinical data obtained from the clinical registry CORECT were retrospectively analyzed. The shortest survival was observed in patients with tumors harboring G12V or G12A KRAS mutation (G12V/A). The median progression-free survival (PFS) and overall survival (OS) for patients with tumors harboring G12V/A KRAS mutation was 6.6 and 16.8 compared to 11.6 and 26.3 months for patients with tumors harboring other KRAS mutation type (p < 0.001 and p < 0.001), while the survival of patients harboring other KRAS mutation types was comparable to those with tumors harboring wild-type KRAS gene. In the Cox multivariable analysis, KRAS G12V/A mutation type remains a significant factor predicting both PFS (HR = 2.18, p < 0.001) and OS (HR = 2.58, p < 0.001). In conclusion, the results of the present study indicate that there is a significant difference in biological behavior between tumors harboring G12V/A and other KRAS mutations. Moreover, comparison of the survival of patients with tumors harboring G12V/A KRAS mutations with those harboring wild-type KRAS gene revealed that G12V/A KRAS mutations are prognostic biomarker for inferior PFS and OS in patients with mCRC treated with bevacizumab in univariate as well as multivariable analyses.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a alely $7 D000483
650    _2
$a bevacizumab $x terapeutické užití $7 D000068258
650    _2
$a kodon $7 D003062
650    _2
$a kolorektální nádory $x farmakoterapie $x genetika $x mortalita $x patologie $7 D015179
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a opakovaná terapie $7 D019233
650    _2
$a výsledek terapie $7 D016896
650    _2
$a ras proteiny $x genetika $7 D018631
655    _2
$a časopisecké články $7 D016428
700    1_
$a Buchler, Tomas $u Department of Oncology and First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
700    1_
$a Mohelnikova-Duchonova, Beatrice $u Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Matejka, Vit Martin $u Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University in Prague, alej Svobody 80, CZ-304 60, Pilsen, Czech Republic.
700    1_
$a Holubec, Luboš, $d 1972- $7 xx0068645 $u Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University in Prague, alej Svobody 80, CZ-304 60, Pilsen, Czech Republic.
700    1_
$a Kulhankova, Jana $u Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University in Prague, alej Svobody 80, CZ-304 60, Pilsen, Czech Republic.
700    1_
$a Bortlicek, Zbynek $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Bartouskova, Marie $u Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Liska, Vaclav $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Plzeň, Czech Republic. Department of Surgery, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Topolcan, Ondrej $u Department of Nuclear Medicine, Medical School and Teaching Hospital Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Sedivcova, Monika $u Bioptic Laboratory, Ltd., Molecular Pathology Laboratory, Plzeň, Czech Republic.
700    1_
$a Finek, Jindrich $u Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University in Prague, alej Svobody 80, CZ-304 60, Pilsen, Czech Republic.
773    0_
$w MED00008757 $t Tumour biology the journal of the International Society for Oncodevelopmental Biology and Medicine $x 1423-0380 $g Roč. 37, č. 5 (2016), s. 6823-30
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26662311 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20171213084453 $b ABA008
999    __
$a ok $b bmc $g 1200661 $s 974974
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 37 $c 5 $d 6823-30 $e 20151210 $i 1423-0380 $m Tumor biology $n Tumor Biol $x MED00008757
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace